Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based Cross-Sectional Study
Abstract
1. Introduction
2. Materials and Methods
2.1. Study and Participants
2.2. Procedures
2.3. Measures
2.3.1. Health Belief Model
2.3.2. Data Collection
2.4. Statistical Analysis
3. Results
3.1. Demographics and Baseline Characteristics
3.2. Guardians’ Awareness of HPV and HPV Vaccine
3.3. Guardians’ HPV Vaccine Acceptance for Girls Aged 9–17
3.4. The Channels of Obtaining Information on HPV and HPV Vaccine
3.5. Guardians’ HPV Vaccine Preference and Reasons for Refusing HPV Vaccine
4. Discussion
Limitation
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
HPV | Human Papillomavirus |
WHO | World Health Organization |
NIP | National Immunization Program |
CDC | Centers for Disease Control |
HBM | Health Belief Model |
OR | Odds Ratio |
95%CI | 95% Confidence Interval |
Appendix A
Instructions□
|
1. Your name:__________________________ 2. Your phone number:□□□□□□□□□□□ 3. Your children’s name: __________________________ 4. Your children’s ID number:□□□□□□□□□□□□□□□□□□ 5. Your children’s gender: ①Male ②Female 5.1 Your children’s birthday: □□Day □□Month □□□□Year 6. Your children’s education level? ①Primary school ②Junior high school ③Senior or vocational high school 7. Your children’s household registration province? ①Zhejiang province ②Other province 8. Your relationship with children? ①Father ②Mother ③Grandparents ④Other 9. Your gender: ①Male ②Female 10. Your age: □□Years old 11. Your education level?①Junior high school or lower ②Senior high school ③Undergraduate or above 12. Your marital status? ①Married ②Unmarried ③Other (including divorced or widowed) 13. Your employment status? ①Full-time job ②Part-time job ③Housework and unemployment ④Other 14. In the past year, where was your habitual residence? ①Rural ②Urban 15. In the past year, what was your annual household income? ①Less than 20,000 ②20,000–49,999 ③50,000–99,999 ④More than 100,000 |
16. Do you think the following statement is correct? 16.1 HPV is mainly transmitted through sexual transmission. ①Yes ②No 16.2 Cervical cancer is one of the most common gynecological cancers in China. ①Yes ②No 16.3 HPV vaccination is the most cost-effective way to prevent cervical cancer. ①Yes ②No 16.4 HPV vaccine is recommended for women over 18 years old. ①Yes ②No 16.5 Available HPV vaccines are divided into 2-, 4-, and 9-valent vaccines. ①Yes ②No 17. When is the optimal age for HPV vaccination? ①After birth ②Before first sex ③After first sex ④Any time is OK ⑤Unknown 18. Do you think cervical cancer screening is necessary after HPV vaccination? ①Necessary ②Unnecessary ③Unknown 19. What do you think your children’s risk of HPV infection is? ①Very low ②Low ③Neither low nor high ④High ⑤Very high 20. What do you think your children’s risk of transmitting HPV to others is? ①Very low ②Low ③Neither low nor high ④High ⑤Very high 21. How damaging do you think HPV infection is to your child’s health? ①Absolutely not severe ②Not severe ③Neutral ④Severe ⑤Very severe |
22. Do you think HPV vaccination is important for your children’s health? ①Very unimportant ②Unimportant ③Neutral ④Important ⑤Very important 23. What do you think of the effectiveness of the HPV vaccine? ①Very ineffective ②Ineffective ③Neutral ④Effective ⑤Very effective 24. What do you think of the safety of the HPV vaccine? ①Very unsafe ②Unsafe ③Neutral ④Safe ⑤Very safe 24.1. When do you think it is appropriate to vaccinate children with the HPV vaccine? ①Junior high school ②Senior high school ③Undergraduate ④Above all |
25. Do you know anyone close to you has been diagnosed with cervical cancer? ①Yes ②No 26. Have you or anyone surrounding you received HPV vaccine?【Multiple】 ①Myself ②Family members ③Relatives ④Friends ⑤Classmates ⑥Colleagues ⑦Others___________________________ ⑧None above all 27. Have you heard the negative news about HPV vaccine? ①Yes ②No 28. Has a doctor recommended HPV vaccine for your children? ①Yes ②No |
29. Which of the following channels are your usual access to HPV vaccine information?【Multiple】 ①Television and radio ②Newspapers, magazines and journal ③Mobile phone short message ④School announcement ⑤Government or CDC platform ⑥Social media platform(Wechat, Sina Weibo, Tiktok, etc.) ⑦Medical knowledge platform ⑧Doctor or medical staff ⑨Family members, relatives, or friends ⑩Others ⑪Never heard about this vaccine 30. Which of the following channels is your best access to HPV vaccine information? ①Television and radio ②Newspapers, magazines and journal ③Mobile phone short message ④School announcement ⑤Government or CDC platform ⑥Social media platform(Wechat, Sina Weibo, Tiktok, etc.) ⑦Medical knowledge platform ⑧Doctor or medical staff ⑨Family members, relatives, or friends ⑩Others ⑪Never heard about this vaccine 31. Would you like to receive public education about HPV vaccination through your mobile phone regularly (such as once a month)? ①Yes ②No 32. Which of the following public education platforms about HPV vaccination are you willing to check?【Multiple】 ①Government or CDC platform ②Wechat platform ③Short message ④News-related social media ⑤Live stream or short video ⑥Medical knowledge platform ⑦Others________________________________ ⑧Neither above all |
33. Would you be willing to vaccinate your children with HPV vaccine? ①Yes 33.1 Would you prefer to vaccinate your child with domestic or imported HPV vaccine? ①Domestic vaccine ②Imported vaccine ③Accept any vaccine 33.2 Which HPV vaccine would you prefer to give your children? ①Bivalent vaccine ②Quadrivalent vaccine ③9-valent vaccine ④Accept any vaccine This is the end of the survey, thank you very much for your participation! |
②No 33.3 Which of the following reasons are you reluctant to vaccinate your children with HPV vaccine?【Multiple】 ①HPV vaccine prices expensive ②Concerns about HPV vaccine safety ③Concerns about HPV vaccine effectiveness ④Child is too young to vaccine ⑤Child is at low infection risk ⑥Wait until better vaccine ⑦Wait for free vaccination policy ⑧Others______________________ 33.4 Which of the following reasons is your most important reluctant to vaccinate your children with HPV vaccine? ①HPV vaccine prices expensive ②Concerns about HPV vaccine safety ③Concerns about HPV vaccine effectiveness ④Child is too young to vaccine ⑤Child is at low infection risk ⑥Wait until better vaccine ⑦Wait for free vaccination policy ⑧Others______________________ This is the end of the survey, thank you very much for your participation! |
References
- eClinicalMedicine. Global strategy to eliminate cervical cancer as a public health problem: Are we on track? eClinicalMedicine 2023, 55, 101842. [Google Scholar] [CrossRef] [PubMed]
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Huang, M.; Zhu, Y.; Zeng, H.; Zhang, F. Temporal trends in incidence and mortality of cervical cancer in China from 1990 to 2019 and predictions for 2034. Eur. J. Cancer Prev. 2024, 33, 252–261. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Ervik, M.; Lam, F.; Laversanne, M.; Colombet, M.; Mery, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today; International Agency for Research on Cancer: Lyon, France, 2022; Available online: https://gco.iarc.who.int/today (accessed on 21 April 2025).
- Bonjour, M.; Charvat, H.; Franco, E.L.; Pineros, M.; Clifford, G.M.; Bray, F.; Baussano, I. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: A birth cohort analysis. Lancet Public Health 2021, 6, e510–e521. [Google Scholar] [CrossRef]
- Yu, Y.Q.; Hao, J.Q.; Mendez, M.J.; Mohamed, S.B.; Fu, S.L.; Zhao, F.H.; Qiao, Y.L. The Prevalence of Cervical HPV Infection and Genotype Distribution in 856,535 Chinese Women with Normal and Abnormal Cervical Lesions: A Systemic Review. J. Cytol. 2022, 39, 137–147. [Google Scholar] [CrossRef]
- Rahangdale, L.; Mungo, C.; O’Connor, S.; Chibwesha, C.J.; Brewer, N.T. Human papillomavirus vaccination and cervical cancer risk. BMJ 2022, 379, e070115. [Google Scholar] [CrossRef]
- World Health Organization. Human papillomavirus vaccines: WHO position paper (2022 update). Wkly. Epidemiol. Rec. 2022, 97, 645–672. [Google Scholar]
- World Health Organization. HPV Vaccine Included in National Immunization Programme. Available online: https://app.powerbi.com/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9 (accessed on 22 April 2025).
- National Health Commission. Action plan for accelerating the elimination of cervical cancer (2023–2030). Chin. J. Viral Dis. 2023, 13, 243–244. [Google Scholar]
- Zhao, Y.; Sun, Y.; Li, Z.; Ma, J.; Wang, F.; Jia, B. HPV vaccination willingness among 3,081 secondary school parents in China’s capital. Hum. Vaccin. Immunother. 2025, 21, 2477383. [Google Scholar] [CrossRef]
- Shi, J.; Zhang, X.; Zheng, H.; Yu, W. Awareness and acceptance of human papillomavirus vaccine among parents of adolescents in Chinese mainland: A meta-analysis. Chin. J. Vaccines Immun. 2019, 25, 464–470. [Google Scholar]
- Tan, S.; Wang, S.; Zou, X.; Jia, X.; Tong, C.; Yin, J.; Lian, X.; Qiao, Y. Parental willingness of HPV vaccination in Mainland China: A meta-analysis. Hum. Vaccin. Immunother. 2024, 20, 2314381. [Google Scholar] [CrossRef]
- Otto, A.K.; Ketcher, D.; McCormick, R.; Davis, J.L.; McIntyre, M.R.; Liao, Y.; Reblin, M.; Vadaparampil, S.T. Using the health belief model to assess racial/ethnic disparities in cancer-related behaviors in an NCI-designated comprehensive cancer center catchment area. Cancer Causes Control 2021, 32, 1085–1094. [Google Scholar] [CrossRef]
- Janz, N.K.; Becker, M.H. The Health Belief Model: A decade later. Health Educ. Q. 1984, 11, 1–47. [Google Scholar] [CrossRef]
- Nguyen, N.Y.; Okeke, E.; Anglemyer, A.; Brock, T. Identifying Perceived Barriers to Human Papillomavirus Vaccination as a Preventative Strategy for Cervical Cancer in Nigeria. Ann. Glob. Health 2020, 86, 118. [Google Scholar] [CrossRef] [PubMed]
- Schwendener, C.L.; Kiener, L.M.; Jafflin, K.; Rouached, S.; Juillerat, A.; Meier, V.; Maurer, S.S.; Muggli, F.; Gültekin, N.; Baumann, A.; et al. HPV vaccine awareness, knowledge and information sources among youth in Switzerland: A mixed methods study. BMJ Open 2022, 12, e054419. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Shi, J.; Zhang, X.; Guo, X.; Yu, W. Willingness of parents of 9-to-18-year-old females in China to vaccinate their daughters with HPV vaccine. Vaccine 2023, 41, 130–135. [Google Scholar] [CrossRef]
- Huang, Y.; Ling, J.; Zhao, X.; Lv, Q.; Wang, L.; Wu, Q.; Xu, S.; Zhang, X. Are HPV Vaccines Well Accepted among Parents of Adolescent Girls in China? Trends, Obstacles, and Practical Implications for Further Interventions: A Five-Year Follow-Up Study. Vaccines 2024, 12, 1073. [Google Scholar] [CrossRef] [PubMed]
- Smolarczyk, K.; Duszewska, A.; Drozd, S.; Majewski, S. Parents’ Knowledge and Attitude towards HPV and HPV Vaccination in Poland. Vaccines 2022, 10, 228. [Google Scholar] [CrossRef]
- Bayram Değer, V.; Yiğitalp, G. Level of hesitation of parents about childhood vaccines and affecting factors: A cross-sectional study in Turkey. BMC Public Health 2024, 24, 2494. [Google Scholar] [CrossRef]
- Lin, Y.; Su, Z.; Chen, F.; Zhao, Q.; Zimet, G.D.; Alias, H.; He, S.; Hu, Z.; Wong, L.P. Chinese mothers’ intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: A study in Fujian Province. Hum. Vaccin. Immunother. 2021, 17, 304–315. [Google Scholar] [CrossRef]
- Lindsay, A.C.; Pineda, J.A.; Valdez, M.J.; Torres, M.I.; Granberry, P.J. Central American Immigrant Parents’ Awareness, Acceptability, and Willingness to Vaccinate Their Adolescent Children Against Human Papillomavirus: A Pilot Cross-Sectional Study. Int. J. Environ. Res. Public Health 2020, 17, 2869. [Google Scholar] [CrossRef]
- Guo, Q.; Zhou, W.; Wen, X.; Lu, J.; Lu, X.; Lu, Y. Discrepancy of human papillomavirus vaccine uptake and intent between girls 9–14 and their mothers in a pilot region of Shanghai, China. Hum. Vaccin. Immunother. 2022, 18, 2132801. [Google Scholar] [CrossRef]
- Gray, A.; Fisher, C.B. Factors associated with HPV vaccine acceptability and hesitancy among Black mothers with young daughters in the United States. Front. Public Health 2023, 11, 1124206. [Google Scholar] [CrossRef]
- Baldwin, A.S.; Tiro, J.A.; Zimet, G.D. Broad perspectives in understanding vaccine hesitancy and vaccine confidence: An introduction to the special issue. J. Behav. Med. 2023, 46, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Yao, X.; He, W.; Wu, X.; Gu, J.; Zhang, J.; Lin, B.; Bi, Z.; Su, Y.; Huang, S.; Hu, Y.; et al. Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls. Hum. Vaccin. Immunother. 2022, 18, 2061248. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Chen, L. Investigation on cognition, vaccination intention and related factors of parents of middle school students about HPV and its vaccine in Yuzhong District of Chongqing. J. Mod. Med. Health 2024, 40, 2799–2803. [Google Scholar]
- Fu, L.Y.; Zimet, G.D.; Latkin, C.A.; Joseph, J.G. Social Networks for Human Papillomavirus Vaccine Advice Among African American Parents. J. Adolesc. Health 2019, 65, 124–129. [Google Scholar] [CrossRef]
- Wang, X.; Feng, Y.; Zhang, Q.; Ye, L.; Cao, M.; Liu, P.; Liu, S.; Li, S.; Zhang, J. Parental preference for Haemophilus influenzae type b vaccination in Zhejiang Province, China: A discrete choice experiment. Front. Public Health 2022, 10, 967693. [Google Scholar] [CrossRef]
- Ramanadhan, S.; Fontanet, C.; Teixeira, M.; Mahtani, S.; Katz, I. Exploring attitudes of adolescents and caregivers towards community-based delivery of the HPV vaccine: A qualitative study. BMC Public Health 2020, 20, 1531. [Google Scholar] [CrossRef]
- Choi, J.; Tamí-Maury, I.; Cuccaro, P.; Kim, S.; Markham, C. Digital Health Interventions to Improve Adolescent HPV Vaccination: A Systematic Review. Vaccines 2023, 11, 249. [Google Scholar] [CrossRef] [PubMed]
- Huang, C.; Yan, D.; Liang, S. The Relationship between Information Dissemination Channels, Health Belief, and COVID-19 Vaccination Intention: Evidence from China. J. Environ. Public Health 2023, 2023, 6915125. [Google Scholar] [CrossRef] [PubMed]
- Shegog, R.; Savas, L.S.; Healy, C.M.; Frost, E.L.; Coan, S.P.; Gabay, E.K.; Preston, S.M.; Spinner, S.W.; Wilbur, M.; Becker, E.; et al. AVPCancerFree: Impact of a digital behavior change intervention on parental HPV vaccine -related perceptions and behaviors. Hum. Vaccin. Immunother. 2022, 18, 2087430. [Google Scholar] [CrossRef] [PubMed]
- Lin, Z.; Chen, S.; Su, L.; Liao, Y.; Chen, H.; Hu, Z.; Chen, Z.; Fang, Y.; Liang, X.; Chen, J.; et al. Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9–17 years in China: A cross-sectional study. BMC Med. 2024, 22, 328. [Google Scholar] [CrossRef] [PubMed]
- Mihretie, G.N.; Liyeh, T.M.; Ayele, A.D.; Belay, H.G.; Yimer, T.S.; Miskr, A.D. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: A community-based cross-sectional study. Reprod. Health 2022, 19, 136. [Google Scholar] [CrossRef]
- López, N.; de la Cueva, I.S.; Taborga, E.; de Alba, A.F.; Cabeza, I.; Raba, R.M.; Marès, J.; Company, P.; Herrera, B.; Cotarelo, M. HPV knowledge and vaccine acceptability: A survey-based study among parents of adolescents (KAPPAS study). Infect. Agents Cancer 2022, 17, 55. [Google Scholar] [CrossRef]
Characteristics | Cases (n) | Proportion (%) |
---|---|---|
Children’s characteristics | ||
Age | ||
9 to 11 years old | 722 | 33.47 |
12 to 14 years old | 710 | 32.92 |
15 to 17 years old | 725 | 33.61 |
Children’s education | ||
Primary school | 859 | 39.82 |
Junior high school | 670 | 31.06 |
Senior or vocational high school | 628 | 29.11 |
Household registration province | ||
Zhejiang province | 2059 | 95.46 |
Other province | 98 | 4.54 |
Guardians’ characteristics | ||
Relationship with children | ||
Father | 466 | 21.60 |
Mother | 1659 | 76.91 |
Grandparents | 3 | 0.14 |
Other | 29 | 1.34 |
Education | ||
Junior high school or lower | 562 | 26.05 |
Senior high school | 481 | 22.30 |
Undergraduate or above | 1114 | 51.65 |
Marital status | ||
Married | 2043 | 94.71 |
Unmarried | 25 | 1.16 |
Other (including divorced or widowed) | 89 | 4.13 |
Employment status | ||
Full-time job | 1665 | 77.19 |
Part-time job | 147 | 6.82 |
Housework and unemployment | 302 | 14.00 |
Other | 43 | 1.99 |
Habitual residence | ||
Urban | 1574 | 72.97 |
Rural | 583 | 27.03 |
Annual household income, CNY (USD) | ||
Less than 20,000 (2789) | 221 | 10.25 |
20,000–49,999 (2789–6972) | 410 | 19.01 |
50,000–99,999 (6972–13,944) | 651 | 30.18 |
More than 100,000 (13,944) | 875 | 40.57 |
HPV vaccine acceptance | 1870 | 86.69 |
Variables | Correct Cases (n) | Proportion (%) |
---|---|---|
Know HPV transmission routes | 1469 | 68.10 |
Know cervical cancer | 1967 | 91.19 |
Know HPV vaccine could defend against cervical cancer most effectively | 1887 | 87.48 |
Know recommended population for HPV vaccination | 602 | 27.91 |
Know HPV vaccine valence | 1812 | 84.01 |
Know optimal HPV vaccination time | 1429 | 66.25 |
Know cervical cancer screening | 1928 | 89.38 |
Average score (Mean ± SD) | 5.14 ± 1.69 |
Variables | Total (n = 2157) | Refuse to Vaccinate (n = 287) | Intend to Vaccinate (n = 1870) | Statistic | p |
---|---|---|---|---|---|
HPV knowledge | |||||
HPV knowledge score | χ2 = 65.85 | <0.001 | |||
Low (0–5 points) | 922 (42.74) | 186 (20.17) | 736 (79.83) | ||
High (6–7 points) | 1235 (57.26) | 101 (8.18) | 1134 (91.82) | ||
Questions related to disease | |||||
HPV infection risk | U = 218,543.00 | <0.001 | |||
Very low | 640 (29.67) | 117 (18.28) | 523 (81.72) | ||
Low | 415 (19.24) | 53 (12.77) | 362 (87.23) | ||
Neutral | 716 (33.19) | 95 (13.27) | 621 (86.73) | ||
High | 239 (11.08) | 14 (5.86) | 225 (94.14) | ||
Very high | 147 (6.82) | 8 (5.44) | 139 (94.56) | ||
HPV transmission risk | U = 229,555.50 | <0.001 | |||
Very low | 687 (31.85) | 120 (17.47) | 567 (82.53) | ||
Low | 366 (16.97) | 38 (10.38) | 328 (89.62) | ||
Neutral | 597 (27.68) | 88 (14.74) | 509 (85.26) | ||
High | 284 (13.17) | 25 (8.80) | 259 (91.20) | ||
Very high | 223 (10.34) | 16 (7.17) | 207 (92.83) | ||
HPV infection damage | U = 213,103.00 | <0.001 | |||
Absolutely not severe | 55 (2.55) | 13 (23.64) | 42 (76.36) | ||
Not severe | 36 (1.67) | 11 (30.56) | 25 (69.44) | ||
Neutral | 332 (15.39) | 73 (21.99) | 259 (78.01) | ||
Severe | 681 (31.57) | 87 (12.78) | 594 (87.22) | ||
Very severe | 1053 (48.82) | 103 (9.78) | 950 (90.22) | ||
Anyone surrounding me diagnosed with cervical cancer | χ2 = 7.22 | 0.007 | |||
No | 1621 (75.15) | 234 (14.44) | 1387 (85.56) | ||
Yes | 536 (24.85) | 53 (9.89) | 483 (90.11) | ||
Questions related to vaccine | |||||
Anyone surrounding me received HPV vaccine | χ2 = 130.48 | <0.001 | |||
Nobody | 379 (17.57) | 119 (31.40) | 260 (68.60) | ||
Myself or someone close to me | 1778 (82.43) | 168 (9.45) | 1610 (90.55) | ||
Importance of HPV vaccine | U = 124,015.50 | < 0.001 | |||
Very unimportant | 15 (0.70) | 8 (53.33) | 7 (46.67) | ||
Unimportant | 34 (1.58) | 25 (73.53) | 9 (26.47) | ||
Neutral | 195 (9.04) | 94 (48.21) | 101 (51.79) | ||
Important | 605 (28.05) | 94 (15.54) | 511 (84.46) | ||
Very important | 1308 (60.64) | 66 (5.05) | 1242 (94.95) | ||
Effectiveness of HPV vaccine | U = 141,993.50 | <0.001 | |||
Very ineffective | 5 (0.23) | 4 (80.00) | 1 (20.00) | ||
Ineffective | 18 (0.83) | 11 (61.11) | 7 (38.89) | ||
Neutral | 606 (28.09) | 172 (28.38) | 434(71.62) | ||
Effective | 853 (39.55) | 72 (8.44) | 781 (91.56) | ||
Very effective | 675 (31.29) | 28 (4.15) | 647 (95.85) | ||
Safety of HPV vaccine | U = 137,732.50 | <0.001 | |||
Very unsafe | 4 (0.19) | 3 (75.00) | 1 (25.00) | ||
Unsafe | 20 (0.93) | 11 (55.00) | 9 (45.00) | ||
Neutral | 586 (27.17) | 178 (30.38) | 408 (69.62) | ||
Safe | 932 (43.21) | 69 (7.40) | 863 (92.60) | ||
Very safe | 615 (28.51) | 26 (4.23) | 589 (95.77) | ||
Actual age less than intended age | |||||
Yes | 1560 (72.32) | 256 (16.41) | 1304 (83.59) | χ2 = 47.10 | <0.001 |
No | 597 (27.68) | 31 (5.19) | 566 (94.81) | ||
Heard negative news about HPV vaccine | χ2 = 15.13 | <0.001 | |||
No | 1463 (67.83) | 166 (11.35) | 1297 (88.65) | ||
Yes | 694 (32.17) | 121 (17.44) | 573 (82.56) | ||
Doctor recommended HPV vaccine | χ2 = 75.26 | <0.001 | |||
No | 1117 (51.78) | 217 (19.43) | 900 (80.57) | ||
Yes | 1040 (48.22) | 70 (6.73) | 970 (93.27) |
Variables | Step 1 | Step 2 | Step 3 | Step 4 | ||||
---|---|---|---|---|---|---|---|---|
p Value | OR [95%CI] | p Value | OR [95%CI] | p Value | OR [95%CI] | p Value | OR [95%CI] | |
Demographic Variables | ||||||||
Education | ||||||||
Junior high school or lower | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
Senior high school | 0.068 | 0.73 (0.52–1.02) | 0.014 | 0.64 (0.45–0.91) | 0.024 | 0.63 (0.42–0.94) | 0.009 | 0.57 (0.37–0.87) |
Undergraduate or above | 0.248 | 1.25 (0.86–1.81) | 0.985 | 1.00 (0.67–1.47) | 0.822 | 0.95 (0.61–1.48) | 0.348 | 0.80 (0.50–1.27) |
Employment status | ||||||||
Full-time job | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
Part-time job | 0.947 | 1.02 (0.62–1.65) | 0.893 | 1.04 (0.63–1.71) | 0.222 | 1.43 (0.81–2.52) | 0.246 | 1.41 (0.79–2.53) |
Housework and unemployment | 0.128 | 0.76 (0.53–1.08) | 0.270 | 0.81 (0.56–1.18) | 0.999 | 1.00 (0.65–1.53) | 0.935 | 1.02 (0.66–1.57) |
Other | 0.267 | 1.82 (0.63–5.20) | 0.197 | 2.05 (0.69–6.12) | 0.433 | 1.63 (0.48–5.51) | 0.342 | 1.85 (0.52–6.59) |
Habitual residence | ||||||||
Rural | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
Urban | 0.800 | 0.96 (0.71–1.30) | 0.455 | 0.89 (0.65–1.21) | 0.301 | 0.83 (0.58–1.18) | 0.232 | 0.80 (0.55–1.15) |
Annual household income (CNY) | ||||||||
Less than 20,000 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | ||||
20,000–49,999 | 0.068 | 1.46 (0.97–2.18) | 0.156 | 1.36 (0.89–2.06) | 0.141 | 1.43 (0.89–2.32) | 0.204 | 1.38 (0.84–2.26) |
50,000–99,999 | <0.001 | 2.18 (1.45–3.29) | 0.002 | 1.94 (1.27–2.98) | 0.012 | 1.86 (1.14–3.02) | 0.036 | 1.70 (1.03–2.80) |
More than 100,000 | <0.001 | 2.39 (1.54–3.72) | <0.001 | 2.19 (1.39–3.45) | 0.010 | 1.99 (1.18–3.34) | 0.015 | 1.94 (1.14–3.32) |
HPV Perceptions | ||||||||
HPV knowledge score | ||||||||
Low | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
High | <0.001 | 2.17 (1.63–2.89) | 0.146 | 1.28 (0.92–1.77) | 0.315 | 1.19 (0.85–1.67) | ||
HPV infection risk | ||||||||
Very low | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
Low | 0.106 | 1.45 (0.92–2.29) | 0.054 | 1.66 (0.99–2.77) | 0.072 | 1.61 (0.96–2.70) | ||
Neutral | 0.005 | 1.90 (1.21–2.96) | 0.009 | 1.95 (1.18–3.23) | 0.036 | 1.74 (1.04–2.93) | ||
High | <0.001 | 3.95 (1.91–8.20) | 0.002 | 3.55 (1.60–7.86) | 0.006 | 3.15 (1.40–7.10) | ||
Very high | 0.014 | 3.15 (1.26–7.87) | 0.100 | 2.39 (0.85–6.75) | 0.135 | 2.25 (0.78–6.55) | ||
HPV transmission risk | ||||||||
Very low | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
Low | 0.259 | 1.33 (0.81–2.19) | 0.514 | 1.20 (0.69–2.09) | 0.507 | 1.21 (0.69–2.11) | ||
Neutral | 0.711 | 0.92 (0.58–1.44) | 0.510 | 0.84 (0.50–1.41) | 0.732 | 0.91 (0.54–1.55) | ||
High | 0.619 | 0.86 (0.47–1.56) | 0.056 | 0.52 (0.27–1.02) | 0.068 | 0.53 (0.27–1.05) | ||
Very high | 0.682 | 1.16 (0.58–2.32) | 0.794 | 0.90 (0.41–1.97) | 0.854 | 0.93 (0.42–2.05) | ||
HPV infection damage | ||||||||
Absolutely not severe | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
Not severe | 0.138 | 0.47 (0.17–1.28) | 0.311 | 0.53 (0.15–1.82) | 0.139 | 0.38 (0.11–1.36) | ||
Neutral | 0.441 | 0.75 (0.36–1.57) | 0.602 | 0.78 (0.30–2.00) | 0.407 | 0.66 (0.24–1.77) | ||
Severe | 0.739 | 1.13 (0.55–2.31) | 0.509 | 0.73 (0.29–1.83) | 0.381 | 0.65 (0.25–1.70) | ||
Very severe | 0.227 | 1.54 (0.76–3.12) | 0.441 | 0.70 (0.28–1.74) | 0.293 | 0.60 (0.23–1.56) | ||
Vaccine Attitudes | ||||||||
Importance of HPV vaccine | ||||||||
Very unimportant | 1.00 (Reference) | 1.00 (Reference) | ||||||
Unimportant | 0.266 | 0.42 (0.09–1.93) | 0.476 | 0.56 (0.11–2.76) | ||||
Neutral | 0.724 | 0.79 (0.21–2.98) | 0.818 | 0.85 (0.21–3.45) | ||||
Important | 0.259 | 2.16 (0.57–8.18) | 0.233 | 2.35 (0.58–9.62) | ||||
Very important | 0.009 | 6.00 (1.55–23.14) | 0.009 | 6.70 (1.61–27.83) | ||||
Effectiveness of HPV vaccine | ||||||||
Very ineffective | 1.00 (Reference) | 1.00 (Reference) | ||||||
Ineffective | 0.139 | 8.93 (0.49–162.46) | 0.258 | 5.56 (0.28–108.59) | ||||
Neutral | 0.048 | 13.97 (1.03–189.88) | 0.101 | 9.47 (0.65–138.67) | ||||
Effective | 0.039 | 15.58 (1.14–212.07) | 0.088 | 10.32 (0.71–151.00) | ||||
Very effective | 0.039 | 15.73 (1.14–216.66) | 0.094 | 10.01 (0.68–148.01) | ||||
Safety of HPV vaccine | ||||||||
Very unsafe | 1.00 (Reference) | 1.00 (Reference) | ||||||
Unsafe | 0.853 | 0.76 (0.04–13.31) | 0.939 | 0.89 (0.05–16.98) | ||||
Neutral | 0.957 | 0.93 (0.07–12.37) | 0.979 | 1.04 (0.07–15.12) | ||||
Safe | 0.553 | 2.21 (0.16–30.18) | 0.629 | 1.95 (0.13–29.27) | ||||
Very safe | 0.501 | 2.50 (0.17–35.90) | 0.626 | 1.98 (0.13–31.29) | ||||
Actual age less than intended age | ||||||||
No | 1.00 (Reference) | 1.00 (Reference) | ||||||
Yes | <0.001 | 0.48 (0.32–0.74) | <0.001 | 0.49 (0.32–0.75) | ||||
Cues to Action | ||||||||
Anyone surrounding me diagnosed with cervical cancer | ||||||||
No | 1.00 (Reference) | |||||||
Yes | 0.438 | 0.86 (0.59–1.26) | ||||||
Anyone surrounding me received HPV vaccine | ||||||||
No | 1.00 (Reference) | |||||||
Yes | <0.001 | 2.03 (1.41–2.92) | ||||||
Heard negative news about HPV vaccine | ||||||||
No | 1.00 (Reference) | |||||||
Yes | 0.001 | 0.59 (0.43–0.82) | ||||||
Doctor recommended HPV vaccine | ||||||||
No | 1.00 (Reference) | |||||||
Yes | <0.001 | 2.32 (1.65–3.25) | ||||||
Hosmer and Lemeshow test | χ2 (df) = 2.84 (7), p = 0.90 | χ2 (df) = 2.98 (8), p = 0.94 | χ2 (df) = 14.97 (8), p = 0.06 | χ2 (df) = 5.29 (8), p = 0.73 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zheng, S.; Deng, X.; Li, L.; Luo, F.; He, H.; Wang, Y.; Xu, X.; Wang, S.; Chen, Y. Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based Cross-Sectional Study. Vaccines 2025, 13, 840. https://doi.org/10.3390/vaccines13080840
Zheng S, Deng X, Li L, Luo F, He H, Wang Y, Xu X, Wang S, Chen Y. Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based Cross-Sectional Study. Vaccines. 2025; 13(8):840. https://doi.org/10.3390/vaccines13080840
Chicago/Turabian StyleZheng, Shuhan, Xuan Deng, Li Li, Feng Luo, Hanqing He, Ying Wang, Xiaoping Xu, Shenyu Wang, and Yingping Chen. 2025. "Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based Cross-Sectional Study" Vaccines 13, no. 8: 840. https://doi.org/10.3390/vaccines13080840
APA StyleZheng, S., Deng, X., Li, L., Luo, F., He, H., Wang, Y., Xu, X., Wang, S., & Chen, Y. (2025). Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based Cross-Sectional Study. Vaccines, 13(8), 840. https://doi.org/10.3390/vaccines13080840